Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing

CAMBRIDGE, Mass., Dec. 8, 2020 -- (Healthcare Sales & Marketing Network) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease, launched today w... Biopharmaceuticals, Venture Capital Remix Therapeutics, REMaster technology
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news